ConductScience.org, home

Paper42585605

Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility.

Hazan J and 3 others. Neurology, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility. Papers, record 42585605. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42585605

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility.
PubMed
Journal
Neurology
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-26
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Alzheimer DiseaseMajor topic
BiomarkersMajor topic
Humans
Primary Health Care

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136745974A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases.EBioMedicine2023https://conductscience.org/library/papers/36745974PubMed
234838239Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.Lancet Neurol2022https://conductscience.org/library/papers/34838239PubMed
339483064Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation.JAMA Neurol2024https://conductscience.org/library/papers/39483064PubMed
439068545Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.JAMA2024https://conductscience.org/library/papers/39068545PubMed
539544104The Italian guideline on diagnosis and treatment of dementia and mild cognitive impairment.Age Ageing2024https://conductscience.org/library/papers/39544104PubMed
640729527Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings.Alzheimers Dement2025https://conductscience.org/library/papers/40729527PubMed
738866966Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.Nat Rev Neurol2024https://conductscience.org/library/papers/38866966PubMed
840145267Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice.Alzheimers Dement2025https://conductscience.org/library/papers/40145267PubMed
98028470Ruling out or ruling in disease with the most sensitive or specific diagnostic test: short cut or wrong turn?Med Decis Making1994https://conductscience.org/library/papers/8028470PubMed
1029710225Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.JAMA Neurol2018https://conductscience.org/library/papers/29710225PubMed
1122740357Principles for high-quality, high-value testing.Evid Based Med2013https://conductscience.org/library/papers/22740357PubMed
1233326253Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.J Clin Oncol2021https://conductscience.org/library/papers/33326253PubMed
1321403122Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact.Circulation2011https://conductscience.org/library/papers/21403122PubMed
1440951924Co-pathology in Alzheimer's disease and Lewy body disease and its association with neuropsychiatric symptoms.Alzheimers Dement2025https://conductscience.org/library/papers/40951924PubMed
1539353147Challenges in a Biological Definition of Alzheimer Disease.Neurology2024https://conductscience.org/library/papers/39353147PubMed
1639044504Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment.J Prev Alzheimers Dis2024https://conductscience.org/library/papers/39044504PubMed
1727683318Measures of Diagnostic Accuracy: Basic Definitions.EJIFCC2009https://conductscience.org/library/papers/27683318PubMed
1835908251The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.Alzheimers Dement2022https://conductscience.org/library/papers/35908251PubMed
1938252443Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.JAMA Neurol2024https://conductscience.org/library/papers/38252443PubMed
2037248905Advancing Diagnostic Certainty in Alzheimer's Disease: A Synthesis of the Diagnostic Process.J Alzheimers Dis2023https://conductscience.org/library/papers/37248905PubMed

See all 21 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42585605

GET https://conductscience.org/api/papers/v1/42585605/references?page=2